

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Brilliance Auto

華 晨 汽 車

BRILLIANCE CHINA AUTOMOTIVE HOLDINGS LIMITED

(華 晨 中 國 汽 車 控 股 有 限 公 司) *

(Incorporated in Bermuda with limited liability)

(Stock Code: 1114)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that with effect from 21st September, 2022, Dr. Lam has been appointed as an independent non-executive Director.

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of Brilliance China Automotive Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that with effect from 21st September, 2022, Dr. Lam Kit Lan, Cynthia (“**Dr. Lam**”) has been appointed as an independent non-executive Director.

The biographical details of Dr. Lam are set out below:

Dr. Lam, aged 54, is currently Chairman and director of Infinergy Hong Kong Ltd, a privately owned company where Dr. Lam is responsible for the group’s overall corporate strategies.

From March 2003 to January 2020, Dr. Lam was the Asia Compliance Officer of Bloomberg L.P. (“**BLP**”), a global financial information services firm. For 8 years during her employment with BLP, she also acted as executive director and Responsible Officer for BLP’s subsidiary Bloomberg Tradebook Hong Kong Limited (“**BTBHK**”), Hong Kong’s first Automated Trading Services (ATS) provider. BTBHK is regulated by the Securities and Futures Commission of Hong Kong (the “**SFC**”) and the Hong Kong Monetary Authority. From 1998 to 2003, she was employed by DBS TD Waterhouse Hong Kong Limited (“**DBSTDW**”) as its executive director and Chief Compliance Officer. DBSTDW was Hong Kong’s first online broker and regulated by the SFC. Prior to 1998, she took on various regional compliance roles with international investment banks and gained regulatory experience having worked in the Enforcement Division of the SFC and the Listing Division of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

* For identification purposes only

Dr. Lam holds a Doctor of Business Administration degree from the Hong Kong Polytechnic University and was recipient of her graduating year's (2007) best thesis award on the topic of Corporate Governance. She received MBA and B. Sc. (Hons) degrees from the University of Toronto in 1993 and 1990, respectively and received LLB (Hons) degree from the University of Wolverhampton in 1998. She is a fellow member of the Hong Kong Institute of Directors (“**HKIoD**”) and of the Hong Kong Securities and Investment Institute (“**HKSI**”). Dr. Lam completed the Executive Diploma in Corporate Governance and Sustainability Directorship jointly organised by the University of Cambridge Institute for Sustainability Leadership and the HKIoD in 2021.

Dr. Lam also contributed her time to various public service appointments, including as member to two Market Misconduct Tribunals in 2007 and 2011, member to the Securities and Futures Appeals Tribunal between 2009 to 2011, member of the Securities and Futures Appeals Tribunal between 2013 to 2015 and former Vice-Chair and Director of the Institute of Securities Dealers Limited. Dr. Lam also acted as former independent non-executive director for HKSI.

Save as disclosed herein, as at the date of this announcement, Dr. Lam (i) does not have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company; (ii) does not have any interests in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not hold other positions within the Group; and (iv) does not have any directorship or major appointment in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Dr. Lam has signed a letter of appointment with the Company for her appointment as an independent non-executive Director for a term of three years commencing from 21st September, 2022 unless terminated by either party giving not less than one month's notice in writing. Dr. Lam is subject to the provisions in the bye-laws of the Company (the “**Bye-Laws**”) relating to retirement by rotation. Moreover, under the Bye-Laws, Dr. Lam will hold the office until the next following annual general meeting of the Company and will retire at that general meeting and shall be eligible for re-election at that meeting. As an independent non-executive Director, the emoluments of Dr. Lam will be determined by the Board with reference to the level of compensation awarded to independent non-executive directors by other companies listed on the Stock Exchange, the responsibilities assumed by Dr. Lam, complexity of the automobile industry and business of the Group, and goodwill as well as reputational value brought to the Company by Dr. Lam. The director's remuneration of Dr. Lam will be subject to annual review by the remuneration committee of the Board.

Dr. Lam has confirmed that she meets the independence guidelines set out in Rule 3.13 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

Save as disclosed above, Dr. Lam confirmed that there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with her appointment and there is no other information that should be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board wishes to express its warm welcome to Dr. Lam on her new appointment to the Board.

By order of the Board
Brilliance China Automotive Holdings Limited
Wu Xiao An
(also known as Ng Siu On)
Chairman

Hong Kong, 20th September, 2022

As at the date of this announcement (given that the appointment of Director takes effect on the date of this announcement), the Board comprises three executive Directors, Mr. Wu Xiao An (also known as Mr. Ng Siu On) (Chairman), Mr. Shen Tie Dong (Chief Executive Officer) and Mr. Zhang Wei; and four independent non-executive Directors, Mr. Song Jian, Mr. Jiang Bo, Mr. Dong Yang and Dr. Lam Kit Lan, Cynthia.